Home

SHEILA GUJRATHI

CIK 1575202 · President & CEO · last filed 2026-07-30

SHEILA GUJRATHI is a President & CEO who has filed 34 SEC Form 4 insider transactions across 8 companies since 2013. The most recent filing, for PCSA, was dated Jul 30, 2026. Across all open-market trades the lifetime net is −$8.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.15M

Companies

8

Total Filings

34

Lifetime Open-Market Net

-$8.02M

Filer Profile

Reported Address
C/O VENTYX BIOSCIENCES, INC.
12790 EL CAMINO REAL, SUITE 200
SAN DIEGO, CA 92130
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PCSA Director — $2.06 — $0 1 2026-07-30
Ventyx Biosciences, Inc. (VTYX) Delisted Director 0 $13.99 $0 -$3.07M 11 2026-03-04
JANX Director 118,889 $20.24 $2.41M $0 6 2025-06-13
Turning Point Therapeutics, Inc. (TPTX) Delisted Director — $76.01 — $0 2 2020-06-17
GOSS President & CEO 4,237,742 $0.18 $742.9K $168.0K 4 2020-02-19
FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted Director — $178.75 — $0 3 2018-05-14
FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted Director — $38.00 — $0 1 2015-12-03
Receptos, Inc. (RCPT) Delisted Chief Medical Officer 12,500 — — -$5.11M 6 2015-08-27

Recent Filings

34 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-30 PCSA Grant (A) — $0 EDGAR
2026-03-04 Ventyx Biosciences, Inc. (VTYX) Delisted Disp (D) −130,000 $0 EDGAR
2025-06-13 JANX Grant (A) +3,750 $0 EDGAR
2025-06-06 Ventyx Biosciences, Inc. (VTYX) Delisted Grant (A) — $0 EDGAR
2024-12-26 Ventyx Biosciences, Inc. (VTYX) Delisted Buy (P) +130,000 $300.6K EDGAR
2024-11-07 JANX Other (J) +4,611 $0 EDGAR
2024-06-28 JANX Grant (A) +2,500 $0 EDGAR
2024-06-07 Ventyx Biosciences, Inc. (VTYX) Delisted Grant (A) — $0 EDGAR
2024-03-04 JANX Other (J) +2,986 $0 EDGAR
2024-01-23 Ventyx Biosciences, Inc. (VTYX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 34
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.